

What is Claimed is:

1. An immediate release compressed tablet for oral delivery of (*R*)-2-amino-3-phenylpropyl carbamate, the tablet comprising:
(*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
at least one binder in an amount of about 1-5% by weight of the tablet; and
at least one lubricant in an amount of about 0.1-2% by weight of the tablet;
wherein the tablet releases at least 85% of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to a subject.
2. The immediate release compressed tablet of claim 1, wherein the tablet releases at least 95% of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to a subject.
3. The immediate release compressed tablet of claim 1 or 2, wherein the tablet does not comprise a disintegrant.
4. The immediate release compressed tablet of any one of claims 1-3, wherein the at least one binder is selected from at least one of hydroxypropyl cellulose, ethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, hydroxyethyl cellulose, povidone, copovidone, pregelatinized starch, dextrin, gelatin, maltodextrin, starch, zein, acacia, alginic acid, carbomers (cross-linked polyacrylates), polymethacrylates, sodium carboxymethylcellulose, guar gum, hydrogenated vegetable oil (type 1), methylcellulose, magnesium aluminum silicate, and sodium alginate.
5. The immediate release compressed tablet of any one of claims 1-4, wherein the at least one lubricant is selected from at least one of magnesium stearate, stearic acid, calcium stearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium stearyl fumarate, and zinc stearate.

6. The immediate release compressed tablet of any one of claims 1-5, comprising:
(*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
hydroxypropyl cellulose in an amount of about 1-5% by weight of the tablet; and
magnesium stearate in an amount of about 0.1-2% by weight of the tablet.
7. The immediate release compressed tablet of any one of claims 1-6, further comprising a coating.
8. The immediate release compressed tablet of claim 7, wherein the coating is a color overcoat.
9. The immediate release compressed tablet of any one of claims 1-8, wherein the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is (*R*)-2-amino-3-phenylpropyl carbamate hydrochloride.
10. The immediate release compressed tablet of any one of claims 1-9, wherein the tablet is oblong in shape.
11. The immediate release compressed tablet of any one of claims 1-10, wherein the tablet comprises about 300 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
12. The immediate release compressed tablet of any one of claims 1-10, wherein the tablet comprises about 150 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
13. The immediate release compressed tablet of any one of claims 1-10, wherein the tablet comprises about 75 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.

14. The immediate release compressed tablet of any one of claims 1-10, wherein the tablet comprises about 37.5 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
15. A method of treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, attention deficit/hyperactivity disorder, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to the subject the immediate release compressed tablet of any one of claims 1-14.
16. The method of claim 15, wherein the tablet is administered once per day.
17. The method of claim 15, wherein the tablet is administered more than once per day.
18. An immediate release compressed tablet for oral delivery of (*R*)-2-amino-3-phenylpropyl carbamate, the tablet comprising (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
wherein the tablet exhibits substantially identical dissolution rates of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof at pH 1.2, pH 4.5, and pH 6.8.
19. The immediate release compressed tablet of claim 18, wherein the tablet releases at least 85% of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to a subject.
20. The immediate release compressed tablet of claim 18 or 19, wherein the tablet releases at least 95% of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to a subject.
21. The immediate release compressed tablet of any one of claims 18-20, wherein the tablet does not comprise a disintegrant.

22. The immediate release compressed tablet of any one of claims 18-21, wherein the tablet comprises:

(*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;

at least one binder in an amount of about 1-5% by weight of the tablet; and

at least one lubricant in an amount of about 0.1-2% by weight of the tablet.

23. The immediate release compressed tablet of claim 22, wherein the at least one binder is selected from at least one of hydroxypropyl cellulose, ethylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, hydroxyethyl cellulose, povidone, copovidone, pregelatinized starch, dextrin, gelatin, maltodextrin, starch, zein, acacia, alginic acid, carbomers (cross-linked polyacrylates), polymethacrylates, sodium carboxymethylcellulose, guar gum, hydrogenated vegetable oil (type 1), methylcellulose, magnesium aluminum silicate, and sodium alginate.

24. The immediate release compressed tablet of any claim 22 or 23, wherein the at least one lubricant is selected from at least one of magnesium stearate, stearic acid, calcium stearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium stearyl fumarate, and zinc stearate.

25. The immediate release compressed tablet of any one of claims 18-24, comprising:
(*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
hydroxypropyl cellulose in an amount of about 1-5% by weight of the tablet; and
magnesium stearate in an amount of about 0.1-2% by weight of the tablet.

26. The immediate release compressed tablet of any one of claims 18-25, further comprising a coating.

27. The immediate release compressed tablet of claim 26, wherein the coating is a color overcoat.

28. The immediate release compressed tablet of any one of claims 18-27, wherein the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is (*R*)-2-amino-3-phenylpropyl carbamate hydrochloride.
29. The immediate release compressed tablet of any one of claims 18-28, wherein the tablet is oblong in shape.
30. The immediate release compressed tablet of any one of claims 18-29, wherein the tablet comprises about 300 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
31. The immediate release compressed tablet of any one of claims 18-29, wherein the tablet comprises about 150 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
32. The immediate release compressed tablet of any one of claims 18-29, wherein the tablet comprises about 75 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
33. The immediate release compressed tablet of any one of claims 18-29, wherein the tablet comprises about 37.5 mg (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof.
34. A method of treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, attention deficit/hyperactivity disorder, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to the subject the compressed tablet or oral dosage form of any one of claims 18-33.
35. The method of claim 34, wherein the tablet or oral dosage form is administered once per day.
36. The method of claim 34, wherein the tablet or oral dosage form is administered more than once per day.

37. An immediate release oral dosage form of (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof, the oral dosage form comprising:
(*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the oral dosage form;
at least one binder in an amount of about 1-5% by weight of the oral dosage form; and
at least one lubricant in an amount of about 0.1-2% by weight of the oral dosage form;
wherein the oral dosage form releases at least 85% of the (*R*)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the oral dosage form to a subject.

38. A method of treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, attention deficit/hyperactivity disorder, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to the subject the compressed tablet or oral dosage form of claim 37.

39. The method of claim 38, wherein the tablet or oral dosage form is administered once per day.

40. The method of claim 38, wherein the tablet or oral dosage form is administered more than once per day.